FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362593748> ?p ?o ?g. }

• W4362593748 endingPage "4971" @default.
• W4362593748 startingPage "4971" @default.
• W4362593748 abstract "Abstract Late-stage diagnoses make ovarian cancer extremely hard to treat. This leads to ovarian cancer accounting for 5% of female cancer deaths and 2.5% of female cancer incidence. Since there are few options for early detection of ovarian cancer, targeted therapies could lead to better outcomes. One target that has been implicated in ovarian cancer, is the transcription factor Signal Transducer and Activator of Transcription 3 (STAT3). STAT3 function is associated with tumor growth, metastasis, drug resistance, angiogenesis, and resistance to apoptosis. These many STAT3 controlled, cancer-associated cellular functions, make it an ideal and versatile target for cancer therapy. Using the Broad institute’s online C.L.U.E. tool and a STAT3 gene signature, we identified statin drugs as potential inhibitors of STAT3 activity. To assess the ability of statins to inhibit STAT3, we treated ovarian cancer spheroids with statins and analyzed STAT3 activity. We have found that statins do not induce a change in the phosphorylation of STAT3 on either tyrosine 705 or serine 727 residues, the two major sites of phosphorylation on STAT3. However, there are other poorly understood post-translational modifications of STAT3, that have previously shown effects on STAT3 function, that may be involved. Importantly, we have observed that statin treatment reduces the viability of Ovcar8 and Heya8 ovarian cancer cell spheroids. We also found that statin treatment induced apoptosis of ovarian spheroids by measuring Annexin V staining. A major problem for ovarian cancer patients is metastasis. Our preliminary evidence suggests that statins reduce the ability of ovarian cancer spheroids to clear a mesothelial monolayer of cells, an early step in ovarian cancer metastasis. There are several membrane-associated signaling proteins, including RAF and RAS, that affect STAT3 activity. Both Ovcar8 and Heya8 spheroids showed a decrease in cell viability with statin treatment, which is partially rescued by geranylgeranyl pyrophosphate (GGPP), a downstream metabolite in the mevalonate pathway. The partial recovery by GGPP indicates a mechanism involving the prenylation of membrane associated proteins. This data shows statins may provide effective treatments for ovarian cancer and defining the mechanisms behind the effects of statins may lead to better therapies and outcomes for ovarian cancer patients Citation Format: Brendan M. Reilly, Sarah J. Miseirvitch, Sarah R. Walker. Identification of statins as a potential treatment for ovarian cancer . [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4971." @default.
• W4362593748 created "2023-04-06" @default.
• W4362593748 creator A5051364166 @default.
• W4362593748 creator A5057314691 @default.
• W4362593748 creator A5079727834 @default.
• W4362593748 date "2023-04-04" @default.
• W4362593748 modified "2023-10-16" @default.
• W4362593748 title "Abstract 4971: Identification of statins as a potential treatment for ovarian cancer " @default.
• W4362593748 doi "https://doi.org/10.1158/1538-7445.am2023-4971" @default.
• W4362593748 hasPublicationYear "2023" @default.
• W4362593748 type Work @default.
• W4362593748 citedByCount "0" @default.
• W4362593748 crossrefType "journal-article" @default.
• W4362593748 hasAuthorship W4362593748A5051364166 @default.
• W4362593748 hasAuthorship W4362593748A5057314691 @default.
• W4362593748 hasAuthorship W4362593748A5079727834 @default.
• W4362593748 hasConcept C121608353 @default.
• W4362593748 hasConcept C126322002 @default.
• W4362593748 hasConcept C143998085 @default.
• W4362593748 hasConcept C190283241 @default.
• W4362593748 hasConcept C2778923194 @default.
• W4362593748 hasConcept C2779013556 @default.
• W4362593748 hasConcept C2780394083 @default.
• W4362593748 hasConcept C2780427987 @default.
• W4362593748 hasConcept C502942594 @default.
• W4362593748 hasConcept C55493867 @default.
• W4362593748 hasConcept C71924100 @default.
• W4362593748 hasConcept C86803240 @default.
• W4362593748 hasConceptScore W4362593748C121608353 @default.
• W4362593748 hasConceptScore W4362593748C126322002 @default.
• W4362593748 hasConceptScore W4362593748C143998085 @default.
• W4362593748 hasConceptScore W4362593748C190283241 @default.
• W4362593748 hasConceptScore W4362593748C2778923194 @default.
• W4362593748 hasConceptScore W4362593748C2779013556 @default.
• W4362593748 hasConceptScore W4362593748C2780394083 @default.
• W4362593748 hasConceptScore W4362593748C2780427987 @default.
• W4362593748 hasConceptScore W4362593748C502942594 @default.
• W4362593748 hasConceptScore W4362593748C55493867 @default.
• W4362593748 hasConceptScore W4362593748C71924100 @default.
• W4362593748 hasConceptScore W4362593748C86803240 @default.
• W4362593748 hasIssue "7_Supplement" @default.
• W4362593748 hasLocation W43625937481 @default.
• W4362593748 hasOpenAccess W4362593748 @default.
• W4362593748 hasPrimaryLocation W43625937481 @default.
• W4362593748 hasRelatedWork W2358524972 @default.
• W4362593748 hasRelatedWork W2791088259 @default.
• W4362593748 hasRelatedWork W2998402275 @default.
• W4362593748 hasRelatedWork W3012878859 @default.
• W4362593748 hasRelatedWork W3114532332 @default.
• W4362593748 hasRelatedWork W3158604434 @default.
• W4362593748 hasRelatedWork W3175984978 @default.
• W4362593748 hasRelatedWork W4283771460 @default.
• W4362593748 hasRelatedWork W4311669536 @default.
• W4362593748 hasRelatedWork W4361824799 @default.
• W4362593748 hasVolume "83" @default.
• W4362593748 isParatext "false" @default.
• W4362593748 isRetracted "false" @default.
• W4362593748 workType "article" @default.